RNC Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$475K Sell
19,094
-50
-0.3% -$1.26K 0.02% 138
2025
Q3
$488K Sell
19,144
-3,411
-15% -$84.2K 0.02% 135
2025
Q2
$547K Buy
22,555
+8,695
+63% +$203K 0.03% 119
2025
Q1
$351K Buy
13,860
+407
+3% +$10.7K 0.02% 137
2024
Q4
$357K Sell
13,453
-40,660
-75% -$1.1M 0.02% 126
2024
Q3
$1.51M Hold
54,113
0.08% 82
2024
Q2
$1.51M Buy
54,113
+3,194
+6% +$87.9K 0.08% 82
2024
Q1
$1.41M Buy
50,919
+13,838
+37% +$384K 0.08% 82
2023
Q4
$1.07M Sell
37,081
-26,801
-42% -$810K 0.06% 92
2023
Q3
$2.12M Sell
63,882
-29,879
-32% -$1.06M 0.13% 71
2023
Q2
$3.44M Buy
93,761
+13,359
+17% +$520K 0.19% 69
2023
Q1
$3.28M Sell
80,402
-1,125
-1% -$48.6K 0.19% 70
2022
Q4
$4.18M Sell
81,527
-7,741
-9% -$371K 0.23% 59
2022
Q3
$3.91M Sell
89,268
-2,219
-2% -$108K 0.25% 66
2022
Q2
$4.8M Buy
91,487
+10,424
+13% +$531K 0.27% 58
2022
Q1
$4.2M Buy
81,063
+25,987
+47% +$1.35M 0.21% 75
2021
Q4
$3.25M Buy
55,076
+1,935
+4% +$95.9K 0.16% 78
2021
Q3
$2.29M Buy
53,141
+134
+0.3% +$5.94K 0.12% 84
2021
Q2
$2.08M Sell
53,007
-1,843
-3% -$71.7K 0.11% 88
2021
Q1
$1.99M Sell
54,850
-13,105
-19% -$465K 0.11% 86
2020
Q4
$2.5M Buy
67,955
+2,112
+3% +$77.5K 0.16% 79
2020
Q3
$2.29M Buy
65,843
+1,120
+2% +$39.3K 0.16% 75
2020
Q2
$2.01M Buy
64,723
+4,431
+7% +$151K 0.14% 73
2020
Q1
$1.87M Sell
60,292
-1,202
-2% -$41K 0.16% 70
2019
Q4
$2.29M Buy
61,494
+4,688
+8% +$167K 0.14% 78
2019
Q3
$1.94M Sell
56,806
-10,574
-16% -$385K 0.14% 74
2019
Q2
$2.77M Buy
67,380
+5,639
+9% +$224K 0.19% 65
2019
Q1
$2.49M Sell
61,741
-2,778
-4% -$111K 0.17% 65
2018
Q4
$2.67M Sell
64,519
-5,686
-8% -$236K 0.2% 60
2018
Q3
$2.94M Sell
70,205
-9,680
-12% -$373K 0.19% 60
2018
Q2
$2.75M Sell
79,885
-1,021,742
-93% -$34.9M 0.19% 57
2018
Q1
$37.1M Sell
1,101,627
-46,418
-4% -$1.6M 2.74% 15
2017
Q4
$39.5M Buy
1,148,045
+7,926
+0.7% +$270K 2.73% 13
2017
Q3
$38.6M Buy
1,140,119
+770
+0.1% +$24.7K 2.91% 12
2017
Q2
$36.3M Buy
1,139,349
+40,705
+4% +$1.28M 2.81% 12
2017
Q1
$35.7M Buy
1,098,644
+46,875
+4% +$1.48M 2.84% 11
2016
Q4
$32.4M Buy
1,051,769
+37,095
+4% +$1.13M 2.68% 10
2016
Q3
$32.6M Buy
1,014,674
+25,411
+3% +$850K 2.9% 10
2016
Q2
$33M Buy
989,263
+5,178
+0.5% +$165K 3.09% 7
2016
Q1
$27.7M Buy
984,085
+14,681
+2% +$419K 2.73% 13
2015
Q4
$29.7M Sell
969,404
-175,538
-15% -$5.52M 2.98% 6
2015
Q3
$34.1M Sell
1,144,942
-18,163
-2% -$582K 3.29% 7
2015
Q2
$37M Sell
1,163,105
-17,959
-2% -$585K 3.15% 10
2015
Q1
$39M Sell
1,181,064
-37,279
-3% -$1.19M 3.27% 8
2014
Q4
$36M Sell
1,218,343
-19,775
-2% -$567K 2.95% 10
2014
Q3
$34.7M Buy
1,238,118
+49,137
+4% +$1.38M 2.79% 13
2014
Q2
$33.5M Buy
1,188,981
+14,391
+1% +$410K 2.7% 15
2014
Q1
$35.8M Buy
1,174,590
+9,100
+0.8% +$271K 3.11% 11
2013
Q4
$33.9M Buy
1,165,490
+22,582
+2% +$657K 3.02% 12
2013
Q3
$31.1M Buy
1,142,908
+40,661
+4% +$1.11M 3.14% 10
2013
Q2
$29.3M Buy
+1,102,247
New +$30.5M 3.1% 8

Other funds holding PFE

RNC Capital Management's PFE Position: Q4 2025 in Review

RNC Capital Management reduced its Pfizer (PFE) stake by 0.26% in Q4 2025, selling an estimated $1.26K and leaving 19,094 shares worth $475K. The position accounts for 0.02% of the portfolio, ranked #138.

RNC Capital Management first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $39.5M in Q4 2017. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • RNC Capital Management held 19,094 shares of Pfizer worth $475K as of Q4 2025.
  • RNC Capital Management sold 50 Pfizer shares in Q4 2025, an estimated $1.26K.
  • Pfizer made up 0.02% of RNC Capital Management's portfolio in Q4 2025, its #138 holding.
  • RNC Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
  • RNC Capital Management's Pfizer position peaked at $39.5M in Q4 2017.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on RNC Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.